| Target Price | HK$20.40 |
| Price | HK$11.61 |
| Potential |
75.71%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Simcere Pharmaceutical Group 2027 .
The average Simcere Pharmaceutical Group target price is HK$20.40.
This is
75.71%
register free of charge
HK$22.53
94.08%
register free of charge
HK$16.77
44.41%
register free of charge
|
|
| A rating was issued by 10 analysts: 9 Analysts recommend Simcere Pharmaceutical Group to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Simcere Pharmaceutical Group stock has an average upside potential 2027 of
75.71%
register free of charge
|
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion HK$ | 9.05 | 11.93 |
| 16.52% | 31.74% | |
| EBITDA Margin | 23.26% | 22.20% |
| 5.55% | 4.54% | |
| Net Margin | 17.38% | 17.10% |
| 59.76% | 1.63% |
7 Analysts have issued a sales forecast Simcere Pharmaceutical Group 2026 . The average Simcere Pharmaceutical Group sales estimate is
This results in the following potential growth metrics:
8 Simcere Pharmaceutical Group Analysts have issued a net profit forecast 2026. The average Simcere Pharmaceutical Group net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share HK$ | 0.63 | 0.79 |
| 85.29% | 25.40% | |
| P/E | 14.21 | |
| EV/Sales | 2.15 |
8 Analysts have issued a Simcere Pharmaceutical Group forecast for earnings per share. The average Simcere Pharmaceutical Group EPS is
This results in the following potential growth metrics and future valuations:
Simcere Pharmaceutical Group...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


